Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ClearPoint Neuro, Inc. (Nasdaq: CLPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ClearPoint Neuro is a medical device company that develops device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine, and its filings offer detailed insight into this business.
Here you can review current and historical Forms 8-K, which ClearPoint Neuro uses to report material events such as preliminary unaudited financial results and significant transactions. For example, the company has filed 8-Ks announcing quarterly and annual financial results, as well as the completion of its acquisition of IRRAS Holdings, Inc., a transaction that expands ClearPoint Neuro’s presence in intracranial fluid management and neurocritical care.
Investors can also use this page to locate annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on revenue by category, operating expenses, and risk factors relevant to ClearPoint Neuro’s neurosurgical navigation, laser therapy, biologics and drug delivery, and intracranial fluid management activities. In addition, registration statements and related documents may describe share issuances connected to mergers or financing arrangements, such as the common stock issued in connection with the IRRAS merger.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of new disclosures. Real-time updates from EDGAR ensure that new CLPT filings, including Forms 4 for insider transactions and proxy materials related to governance and compensation, are available as they are posted. This page is intended as a central resource for analyzing ClearPoint Neuro’s regulatory history, capital structure changes, and material corporate events through its official SEC filings.
ClearPoint Neuro, Inc. ownership update: a group led by Bigger Capital reports beneficial holdings in Common Stock.
As of April 20, 2026, Bigger Capital beneficially owned 1,361,644 shares (approximately 4.54% of the class). District 2 Capital Fund beneficially owned 341,696 shares (approximately 1.14%). Mr. Michael Bigger may be deemed to beneficially own a combined 2,261,340 shares (~7.54%), including shares attributed to family members and an IRA. The percentages are calculated using 29,986,016 shares outstanding as of March 23, 2026.
ClearPoint Neuro, Inc. is asking stockholders to vote at a virtual-only 2026 Annual Meeting on May 20, 2026 at 10:00 a.m. Pacific Time. Holders of 29,986,016 common shares as of March 23, 2026 may participate.
Stockholders will elect seven directors, ratify Cherry Bekaert LLP as independent auditor, cast an advisory say-on-pay vote on executive compensation, and consider approval of the Seventh Amended and Restated 2013 Incentive Compensation Plan. The revised plan would add 1,000,000 shares, increasing the total plan share reserve to 7,806,250, which the company notes is about 3% of fully diluted shares.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director R. John Fletcher received 1,270 shares of common stock as a grant. The shares were issued at $9.10 per share under the company’s incentive compensation plan as payment of fees owed under the Non-Employee Director Compensation Plan.
Following this compensation-related issuance, Fletcher directly holds 117,932 shares of ClearPoint Neuro common stock.
Girin Pascal E R reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Pascal E. R. Girin received 755 shares of Common Stock as compensation. The shares were granted at $9.10 per share under the company’s Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed under the Non-Employee Director Compensation Plan. Following this award, Girin directly holds 98,206 shares of ClearPoint Neuro common stock.
Richards Timothy T. reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Timothy T. Richards received 442 shares of Common Stock as compensation, valued at $9.10 per share. The award was issued under the company’s Sixth Amended and Restated 2013 Incentive Compensation Plan in payment of fees owed under the Non-Employee Director Compensation Plan.
Following this grant, Richards directly holds 80,196 shares of ClearPoint Neuro common stock. The shares were issued at the closing price of the company’s common stock on March 31, 2026, making this a routine, stock-settled director fee payment rather than an open-market purchase.
The Vanguard Group filed Amendment No. 3 on a Schedule 13G/A reporting zero beneficial ownership of ClearPoint Neuro Inc common stock as of 03/13/2026. The filing explains an internal realignment effective 01/12/2026 that caused certain Vanguard subsidiaries to report holdings separately on a "disaggregated basis" in reliance on SEC Release No. 34-39538.
The amendment lists Amount beneficially owned: 0 and Percent of class: 0%, and states Vanguard and its managed accounts have rights to dividends or proceeds where applicable; no other person holds more than 5% according to the filing.
ClearPoint Neuro, Inc. CEO and President Joseph Burnett exercised stock options to acquire 20,942 shares of Common Stock at $3.24 per share. He paid the exercise price in cash and no shares were sold; all shares received were retained.
Following the exercise, Burnett directly owns 116,842 shares of Common Stock. In addition, 193,231 shares are held indirectly through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.
ClearPoint Neuro, Inc. provides an overview of its business and risks as a commercial-stage medical device company focused on minimally invasive neurosurgical procedures and biologics/drug delivery. It reports an aggregate market value of about $328 million for non-affiliate common stock as of June 30, 2025, and 29,663,875 shares outstanding as of March 6, 2026.
The company highlights two integrated components: neurosurgical devices, including the ClearPoint navigation platform, ClearPoint Prism Neuro Laser Therapy System, SmartFrame OR, and the newly added IRRAflow Active Fluid Exchange System from its 2025 IRRAS acquisition; and a growing biologics and drug delivery services business with more than 60 partners. It emphasizes multiple FDA clearances and a De Novo marketing authorization for the SmartFlow Neuro cannula in AADC deficiency, while summarizing extensive risk factors around integration of IRRAS, customer concentration, regulatory approvals, reimbursement, debt, and ongoing losses.
ClearPoint Neuro reported strong top-line growth for 2025 while remaining loss-making and investing heavily for future expansion. Total revenue rose to $37.0 million from $31.4 million, an 18% increase, with fourth-quarter revenue up to $10.4 million from $7.8 million, or 34% growth.
Biologics and drug delivery revenue grew 10% to $19.0 million, and neurosurgery navigation and therapy revenue rose 44% to $14.8 million, while capital equipment and software declined 18% to $3.1 million. Gross margin held at 61%, but operating expenses increased 21% to $46.9 million, driving a wider net loss of $25.5 million versus $18.9 million.
The company completed the IRRAS Holdings acquisition, added access to an extra $20.0 million under its Oberland Capital note facility, and ended 2025 with $45.9 million in cash and cash equivalents, up from $20.1 million. For 2026, ClearPoint Neuro projects revenue between $52.0 million and $56.0 million.